1. Intercontinental Marketing Services (IMS) Health, II Mercato Farmaceutico 2001-2002.
2. Singh G, Miller JD, Huse DM, Pettitt D, D'Agostino RB, Russell MW. Consequences of increased systolic blood pressure in patients with osteoarthrosis and rheumatoid arthritis. J Rheumat. 2003;30(4):714-719.
3. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. Emerging therapeutic strategies on osteoarthritis patients with hypertension. EULAR Sattellite symposium: Optimising the management of osteoarthritis: emerging therapies. Br Med J. 2010;27.
4. Wolfe F, Zhao S, Pettitt D. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol. 2004;31(6):1143-1151.
5. Harris RC, Breyer MD. Update on Cyclooxygenase-2 Inhibitors. Clin J Am Soc Nephrol. 2006;1(2):236-245.